Clinical perspective on desmoplastic small round-cell tumor

Alberto Gil1, Alberto Gomez Portilla, Erwin A Brun

  • 1Washington Cancer Institute, Washington, DC 20010, USA.

Oncology
|November 24, 2004
PubMed

Insights

Desmoplastic small round-cell tumor (DSRCT) is a rare cancer. Aggressive treatment did not improve survival, but early intervention with surgery and chemotherapy may offer future hope.

Area of Science:

  • Oncology
  • Rare Cancers
  • Peritoneal Surface Malignancy

Background:

  • Desmoplastic small round-cell tumor (DSRCT) is a rare, aggressive malignancy primarily affecting young males.
  • Characterized by peritoneal surface involvement and a historically poor prognosis with a mean survival of 29 months.

Purpose of the Study:

  • To analyze clinical and pathological data of DSRCT patients treated at a single institution.
  • To compare outcomes with existing literature data to inform clinical pathway development.
  • To evaluate the efficacy of cytoreductive surgery and intraperitoneal chemotherapy.

Main Methods:

  • Retrospective analysis of 7 DSRCT patients treated at Washington Hospital Center.
  • Comparison with a comprehensive review of DSRCT cases from medical literature.
  • Data collection included clinical presentation, tumor distribution, surgical intervention, and survival outcomes.

Main Results:

  • Common symptoms include abdominal pain, increased girth, and palpable mass.
  • Cytoreductive surgery plus intraperitoneal chemotherapy showed a mean survival of 32 months, not improving upon historical data.
  • Two long-term survivors (55 and 101 months) achieved response with systemic chemotherapy; complete surgical removal did not correlate with survival.

Conclusions:

  • Aggressive treatment strategies did not significantly improve overall survival, likely due to advanced disease stage at diagnosis.
  • Complete surgical resection alone did not correlate with improved survival.
  • A comprehensive approach involving early, complete surgical tumor clearing combined with perioperative systemic and intraperitoneal chemotherapy is proposed for future management.